| 纯度 | > 85 % SDS-PAGE |
| 种属 | Human |
| 靶点 | CCNA2 |
| Uniprot No | P20248 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-432aa |
| 氨基酸序列 | MLGNSAPGPATREAGSALLALQQTALQEDQENINPEKAAPVQQPRTRAALAVLKSGNPRGLAQQQRPKTRRVAPLKDLPVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPRKPLVPLDYPMDGSFESPHTMDMSIILEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPESLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL |
| 预测分子量 | 54.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCNA2重组蛋白的3篇代表性文献及简要摘要：
1. **"Cyclin A2 regulates DNA repair and chromosome stability"**
*作者：Murphy, K.L. et al.*
摘要：研究揭示了CCNA2重组蛋白在DNA损伤修复中的作用，证明其通过调控同源重组修复通路维持基因组稳定性，并影响癌细胞对化疗的敏感性。
2. **"Expression and purification of functional human Cyclin A2 in E. coli"**
*作者：Zhang, Y. et al.*
摘要：开发了一种高效的大肠杆菌表达系统，成功获得具有激酶结合活性的重组CCNA2蛋白，为体外研究细胞周期调控机制提供工具。
3. **"Cyclin A2 as a therapeutic target in triple-negative breast cancer"**
*作者：Li, H. et al.*
摘要：通过重组CCNA2蛋白筛选小分子抑制剂，发现其特异性抑制可阻断三阴性乳腺癌细胞增殖，提示其作为治疗靶点的潜力。
4. **"Structural insights into Cyclin A2-CDK2 complex activation"**
*作者：Brown, N.R. et al.*
摘要：利用重组CCNA2/CDK2复合物的晶体结构分析，揭示了磷酸化修饰对其激酶活性的调控机制，为靶向药物设计提供结构基础。
(注：以上文献为示例性质，实际引用需根据具体研究内容选择权威期刊论文。建议通过PubMed或Web of Science检索最新文献。)
Here’s a concise overview of CCNA2 recombinant protein:
CCNA2 (Cyclin-A2) is a critical regulatory protein involved in cell cycle progression, primarily governing the transition from G1 to S phase and the G2/M checkpoint. Encoded by the *CCNA2* gene, it binds to cyclin-dependent kinases (CDKs), particularly CDK2 and CDK1. to drive DNA replication initiation and mitotic entry. Dysregulation of CCNA2 is strongly associated with uncontrolled cell proliferation in cancers, making it a biomarker for tumorigenesis and a potential therapeutic target.
Recombinant CCNA2 protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. The purified protein retains functional domains necessary for CDK binding and kinase activation, often validated through enzymatic assays and co-immunoprecipitation studies.
Researchers utilize CCNA2 recombinant protein to investigate cell cycle mechanisms, screen CDK inhibitors, and model oncogenic signaling pathways. It serves as a vital tool for structural studies (e.g., X-ray crystallography) to map interaction interfaces with CDKs and inhibitory compounds. In drug discovery, it enables high-throughput testing of anticancer agents targeting the CCNA2-CDK axis. Recent applications also extend to stem cell differentiation studies and viral pathogenesis research, where hijacking of host cell cycle machinery occurs. Quality control metrics include SDS-PAGE verification (>90% purity), mass spectrometry confirmation, and functional activity tests using phosphorylation assays.
×
